Loading
Inflammatory Bowel Disease · Journal article
Synthetic and Systems Biotechnology · July 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing current understanding of Lactiplantibacillus plantarum's proposed mechanisms in inflammatory bowel disease, including microbiota modulation, immunoregulation, antioxidant activity, and barrier function restoration. The source presents a conceptual framework of multi-target effects and discusses synbiotic strategies and delivery systems, but does not report new clinical trial data, effect sizes, or efficacy measures.
Narrative review. Inflammatory bowel disease patients (population reviewed, not studied directly).
L. plantarum is identified as a Gram-positive bacterium found in foods and human mucosal environments with reported safety and adaptability for IBD prevention and management IBD pathogenesis is characterized by gut microbiota dysbiosis, abnormal immune activation, and intestinal mucosal barrier defects that reinforce each other in a vicious cycle Conventional IBD therapies (immunosuppressants and biologics) suffer from low drug response rates and metabolic disturbances, motivating exploration of probiotic adjunctive approaches
No data on safety, adverse events, or clinical outcomes in IBD patients are provided L. plantarum is identified as a Gram-positive bacterium found in foods and human mucosal environments with reported safety and adaptability for IBD prevention and management
This review suggests L. plantarum may merit investigation as an adjunctive therapy for IBD, but clinicians should note that the source presents mechanistic hypotheses and a conceptual framework rather than evidence from clinical trials demonstrating efficacy or safety. Clinical application should await appropriately powered and controlled clinical investigation.
This is a narrative review synthesizing mechanistic theories and prior research on L. plantarum in IBD, presenting a conceptual framework rather than new empirical evidence or clinical trial data.
As stated by the source record.
This review suggests L. plantarum may merit investigation as an adjunctive therapy for IBD, but clinicians should note that the source presents mechanistic hypotheses and a conceptual framework rather than evidence from clinical trials demonstrating efficacy or safety. Clinical application should await appropriately powered and controlled clinical investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory disorders of the bowel, characterized by complex etiologies that are closely associated with an imbalance in intestinal microbiota, abnormal immune activation, and compromised intestinal mucosal barrier function. Current therapeutic options are limited by low response rates and metabolic disorders, underscoring the urgent need for innovative clinical treatments. Lactiplantibacillus plantarum (formerly Lactobacillus plantarum, hereafter referred to as L. plantarum) has emerged as a focal point in IBD research due to its capacity to modulate the intestinal microenvironment and its robust probiotic properties. This review elucidates the multifaceted regulatory mechanisms of L. plantarum in IBD, including its role in modulating host immune responses, mitigating oxidative damage, restoring intestinal mucosal barrier integrity, and reestablishing microbiota balance. Additionally, it highlights advancements in L. plantarum synbiotic research and underscores the necessity for a "basic research-technology translation-clinical application" framework in future investigations, while also exploring the potential of novel targeted delivery technologies. Evidence indicates that L. plantarum enhances intestinal health through multi-target synergy, with its probiotic effects and innovative delivery systems presenting significant application potential. This review offers insights into the mechanisms underlying the action of L. plantarum, establishing a theoretical foundation for the development of novel food therapies aimed at treating IBD. It further contributes to the integration of such therapies within precision medicine approaches for IBD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.